Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

BORIS DOI
Publisher DOI
PubMed ID
20645862
Description
Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL.
Date of Publication
2010
Publication Type
Article
Language(s)
en
Contributor(s)
Opportunistic Infections Project Team of the, Collaboration of Ob
Mocroft, Amanda
Reiss, Peter
Kirk, Ole
Mussini, Cristina
Girardi, Enrico
Morlat, Philippe
Stephan, Christoph
De Wit, Stephane
Doerholt, Katja
Ghosn, Jade
Bucher, Heiner C
Lundgren, Jens D
Chene, Genevieve
Miro, Jose M
Additional Credits
Universitätsklinik für Infektiologie
Series
Clinical infectious diseases
Publisher
Oxford University Press
ISSN
1058-4838
Access(Rights)
open.access
Show full item